AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01371526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depot tetracosactide
Description: 1mg, 3x weekly by sc injection
Study NCT02773056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ischial Ramus Containment (IRC)
Description: Ischial Ramus Containment (IRC) is the standard of care socket
Study NCT02773056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Socket Ischial Ramus Containment (IRC)
Description: Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
Study NCT02773056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Ischial Interface (Sub-I)
Description: Sub-Ischial Interface (Sub-I) is a comparator study socket
Study NCT00806078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324 mg capsules (648 mg)
Study NCT00547898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer 125 mg
Description: Crofelemer 125 mg
Study NCT00547898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer 250 mg
Description: Crofelemer 250 mg
Study NCT00547898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer 500 mg
Description: Crofelemer 500 mg
Study NCT00547898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03040817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric peroral endoscopic pyloromyotomy (G-POEM)
Description: G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point.
Study NCT03040817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole + Mosapride
Description: Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
Study NCT01768338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab combined with SB-485232
Description: Ofatumumab with escalating doses of SB-485232
Study NCT03433144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Solution
Description: the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia
Study NCT03433144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline 0.9%)
Description: An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
Study NCT05205278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
Study NCT01091051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
Study NCT01091051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Soduim Chloride)
Description: Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
Study NCT02277340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EAPA
Description: Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
Study NCT03771690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardised meal
Description: A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
Study NCT01799304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no distractor control group
Description: This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
Study NCT01799304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visual and sound attentional distractors
Description: The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
Study NCT01799304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sound attentional distractor alone
Description: In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
Study NCT01799304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional cognitive task
Description: The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
Study NCT00503737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National Colorectal Cancer Roundtable Toolbox
Study NCT03300258 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Robotic therapy
Description: The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour.
Study NCT03300258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic therapy
Description: The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour.
Study NCT03300258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic therapy
Description: The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
Study NCT03300258 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aerobic therapy
Description: The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
Study NCT03944083 — intervention group
Intervention type: OTHER
Intervention: Treatment as usual for ADHD
Description: Children are given treatment according to diagnostic conclusion and clinical recommendations.
Study NCT03760276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole Oral Product (Vfend®)
Description: To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
Study NCT03235375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously
Study NCT03235375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously
Study NCT02600494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007 (Lumateperone)
Study NCT02600494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03285906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Targeted therapy Apatinib：500 mg，po，qd
Study NCT03579225 — intervention group
Intervention type: DEVICE
Intervention: MATRx plus test
Description: The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
Study NCT02591238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-smoker oral placebo
Description: Participants oral placebo last 2 weeks.
Study NCT02591238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-smoker oral melatonin
Description: Participants oral melatonin 3 mg/day last 2 weeks.
Study NCT02591238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: smoker oral placebo
Description: Participants oral placebo last 2 weeks.
Study NCT02591238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: smoker oral melatonin
Description: Participants oral melatonin 3 mg/day last 2 weeks.
Study NCT01525940 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam Colon Capsule Endoscopy (Given® Diagnostic System)
Description: 2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
Study NCT03293628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Packing
Description: This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
Study NCT03293628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Packing
Description: This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
Study NCT03585673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PM
Description: Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
Study NCT03585673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
Study NCT03917225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-102
Description: Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.
Study NCT03917225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
Study NCT02911623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Lithoplasty® System
Description: The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
Study NCT02297737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Study NCT02297737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Study NCT02073903 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Survey
Study NCT02073903 — intervention group
Intervention type: BEHAVIORAL
Intervention: Provider Survey
Study NCT03487406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: One 90 mg tablet, oral, twice daily for 6 months.
Study NCT03487406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: One 90 mg tablet, oral, twice daily for 6 months.
Study NCT03487406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: One 75 mg tablet, oral, once a day, for 6 months.
Study NCT03487406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: One 75 mg tablet, oral, once a day, for 6 months.
Study NCT03487406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aspirin
Description: Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
Study NCT03487406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Aspirin
Description: Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
Study NCT03487406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ticagrelor
Description: Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
Study NCT03487406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ticagrelor
Description: Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
Study NCT03125577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR22
Description: 4SCAR19 and 4SCAR22
Study NCT03125577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR38
Description: 4SCAR19 and 4SCAR38
Study NCT03125577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR20
Description: 4SCAR19 and 4SCAR20
Study NCT03125577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR123
Description: 4SCAR19 and 4SCAR123
Study NCT03125577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR70
Description: 4SCAR19 and 4SCAR70
Study NCT00354341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Study NCT00354341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Study NCT04525638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Description: 7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
Study NCT04525638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
Study NCT00070057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study NCT00070057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00070057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00070057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00070057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT00070057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00070057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02440568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
Study NCT01024348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extended-release tramadol
Description: 30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
Study NCT02440568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
Study NCT02440568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 0.625mg/m\^2
Study NCT02440568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 1.25mg/m\^2
Study NCT02440568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 2.0mg/m\^2
Study NCT02440568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 3.0mg/m\^2
Study NCT04928274 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ball attachment to retain mandibular over denture
Description: each patient in group receive 3 locator attachment for over denture retention
Study NCT04928274 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: locator attachment to retain mandibular over denture
Description: each patient in group receive 3 locator attachment for over denture retention
Study NCT04928274 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telescopic attachment to retain mandibular over denture
Description: each patient in group receive 3 telescopic attachment for over denture retention
Study NCT03125577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR30
Description: 4SCAR19 and 4SCAR30